HOME >> MEDICINE >> NEWS
Brief, high-dose steroid treatment offers extended relief to giant cell arteritis patients

ATLANTA -- A new study offers both hope and a practical treatment option for patients with giant cell arteritis (GCA). Researchers from Emory University and the Mayo Clinic have found that by treating newly diagnosed GCA patients with just three days of a high-dose intravenous steroid, patients relapsed less in the following year and were able to significantly taper off usage of an oral steroid. The study is published in the October issue of the journal Arthritis & Rheumatism.

Giant cell arteritis is characterized by inflammation of arteries, primarily in the head, and affects 20 out of every 100,000 people. GCA inflammation may lead to swelling and headaches, or, as it progresses, vision loss, strokes and aortic aneurysms. While past research has shown a genetic link to the disease, which primarily affects Caucasian women over the age of 50, there is no known cause or cure.

For the last 40 years, physicians have been able to treat and reverse some symptoms of GCA by prescribing prednisone, to be taken daily over a year or more. "Patients improve promptly and reliably, within days of when we treat them," says Cornelia M. Weyand, MD, PhD, co-director of the Kathleen B. and Mason I. Lowance Center for Human Immunology at Emory University and an author of the paper. "The problem is that patients have to take prednisone for a long time and in high doses, and they are at risk of developing side effects." Common side effects include hypertension, diabetes and osteoporosis.

While scientists have attempted to develop new drugs that would be more effective and have fewer side effects, their results have been unsuccessful. "We and others tried to look into other types of treatments that could help with this disease," says Jrg Goronzy, MD, PhD, senior author of the paper, and co-director of the Lowance Center.

"Even the modern and effective immunosuppressants do not improve the situation with these patients," says Dr. Weyan
'"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University Health Sciences Center
2-Oct-2006


Page: 1 2

Related medicine news :

1. Study examines characteristics of female high school students who report steroid use
2. Female teen steroid use not limited to athletes
3. Bronchial thermoplasty may allow severe asthma patients to wean off oral corticosteroids
4. Inhaled steroids may not be enough for some children with asthma
5. Nonsteroidal anti-inflammatory drugs use associated with higher gastrointestinal complications
6. Short-term topical corticosteroid use may offer relief for patients with acute form of psoriasis
7. Pre-clinical study suggests how steroid can reverse post-traumatic stress
8. Inhaled corticosteroids reduce death in patients with COPD
9. Non-steroidal anti-inflammatory drugs (NSAIDs) and congenital anomalies
10. National trial gives unprecedented support for steroid withdrawal in kidney transplants
11. New study adds weight to argument for steroid injections in patients with hip osteoarthritis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from ... primary eye care practitioners on the latest breakthroughs in the prevention, diagnosis and ... Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer ...
(Date:1/17/2017)... ... , ... Neil H. Greco Insurance Agency, a northern New Jersey firm that ... launching a charity drive to raise awareness of heart disease and promote habits that ... and is responsible for 1 in every 4 deaths at the national level each ...
(Date:1/17/2017)... ... ... Livionex, Inc., a Silicon Valley healthcare company focused on treating biofilms and ... gel that shows significant reduction in plaque levels and gum inflammation and bleeding when ... at the Beckman Laser Institute at UC Irvine and has been published in Dentistry, ...
(Date:1/17/2017)... ... January 17, 2017 , ... The Sharie Withers ... has announced the latest beneficiary of their thriving community involvement program. The current ... to fulfilling the dreams of terminally ill patients. Donations to this worthy cause ...
(Date:1/17/2017)... ... ... Today, FloSports , a global leader in live digital sports and original ... long-term extension of their media partnership. The partnership, which began in 2013, will now ... events exclusively on FloWrestling.com as well as usage of the FloArena meet management software ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 Angel MedFlight Worldwide Air Ambulance is ... Kelly as the keynote speaker at the American ... Washington D.C. April 20-23. Kelly, a ... morning, April 21 at the Gaylord National Resort.  More ... are expected to attend the annual conference. Angel MedFlight ...
(Date:1/17/2017)... , Jan. 17, 2017  Market Research Future published a Half ... Market is expected to reach USD 33.6 million during the period ... Market Highlights ... Global Endoscopy Devices Market has been examined as a swiftly growing ... is huge demand for endoscopy device in various regions.  The increasing ...
(Date:1/17/2017)... 17, 2016  Attorney Advertising -- Bronstein, Gewirtz & Grossman, ... Anthera Pharmaceuticals, Inc. ("Anthera" or the "Company") (NASDAQ: ... and assist the investigation by visiting the firm,s site: ... certain of its officers and/or directors have violated Sections 10(b) ... ...
Breaking Medicine Technology:
Cached News: